Arsenakis M, Georgiou G M, Welsh J K, Cauchi M N, May J T
Int J Cancer. 1980 Jan 15;25(1):67-71. doi: 10.1002/ijc.2910250109.
The incidence of anti-AG-4 complement-fixing antibodies in Australian cervical carcinoma (CaCx), herpes simplex virus (HSV) type 1 and 2, and control patients, was investigated using local HSV strains. The local HSV strains (both HSV-IMI and HSV-2MI) were found, by neutralization experiments, to vary from the American prototype strains. All HSV-2-strains tested were able to induce AG-4 in 4-h infected HEp-2 cells. Anti-AG-4-complement-fixing antibodies were detected in 40% of dysplasia patients, 60% of carcinoma-in-situ patients, 75% of CaCx patients, 65% of CaCx post-operative patients, 88% of HSV-2 patients with active lesions, 10% of HSV-1 patients with active lesions, 10--20% of normal patients and 20% of patients with cancer, other than CaCx. The AG-4 test is tumour-specific in that it distinguishes CaCx from other cancer patients tested, but it cannot distinguish HSV-2 patients from CaCx patients.
使用本地单纯疱疹病毒（HSV）毒株，对澳大利亚宫颈癌（CaCx）、1型和2型单纯疱疹病毒以及对照患者中抗AG - 4补体结合抗体的发生率进行了调查。通过中和实验发现，本地HSV毒株（HSV - IMI和HSV - 2MI）与美国原型毒株不同。所有测试的HSV - 2毒株在感染4小时的HEp - 2细胞中均能诱导产生AG - 4。在40%的发育异常患者、60%的原位癌患者、75%的CaCx患者、65%的CaCx术后患者、88%有活动性病变的HSV - 2患者、10%有活动性病变的HSV - 1患者、10 - 20%的正常患者以及20%除CaCx外的癌症患者中检测到了抗AG - 4补体结合抗体。AG - 4检测具有肿瘤特异性，因为它能将CaCx与其他接受检测的癌症患者区分开来，但无法将HSV - 2患者与CaCx患者区分开来。
